Try our Advanced Search for more refined results
Life Sciences
-
November 25, 2025
Medical AI Co. Accused Of 'Smear Campaign' Against Rivals
Two rivals of medical artificial intelligence platform OpenEvidence have told a Massachusetts federal judge the startup has used the courts in a campaign of "deceit, harassment and defamation" against competitors.
-
November 25, 2025
Investors Say Alexandria Overhyped Leasing, NYC Project
Alexandria Real Estate Equities Inc. investors filed suit in California federal court Tuesday, claiming the real estate investment trust overstated the strength of its leasing business and the projected value of a New York City property, causing the company's stock price to drop once the truth came to light.
-
November 25, 2025
Mich. Pharmacist Gets 46 Months For $4M Fraud Scheme
A former Michigan pharmacist who pled guilty to orchestrating a $4 million Medicare scam was sentenced by a federal judge to 46 months in prison and ordered to pay restitution and forfeit property as part of a plea deal, the U.S. Department of Justice announced.
-
November 25, 2025
Judge Hands SEC Win In Pharma Co.'s CBD Investor Fraud Case
A California federal judge has granted the U.S. Securities and Exchange Commission an early win in its suit against Vivera Pharmaceuticals, its CEO and affiliate Sentar Pharmaceuticals, finding they misled investors about the company's rights to key cannabinoid drug-delivery technology and about how investor money would be spent.
-
November 25, 2025
MVP: Hogan Lovells' Mahvesh A. Qureshi
Mahvesh A. Qureshi, a life sciences partner at Hogan Lovells, advised her client through a deal to acquire Anthos Therapeutics, a biopharmaceutical company that developed a unique stroke treatment, in a transaction that could total $3.1 billion, and led Merck on its up to $1.3 billion purchase of a novel autoimmune drug, earning her a spot as one of the 2025 Law360 Life Sciences MVPs.
-
November 25, 2025
NRDC Tells 9th Circ. EPA Would 'Neuter' Public TSCA Rights
The Natural Resources Defense Council has asked the Ninth Circuit to reject the U.S. Environmental Protection Agency's narrow reading of citizen enforcement rights under the Toxic Substances Control Act, saying it would unfairly restrict challenges to agency inaction.
-
November 24, 2025
Mass. Judge Says States Can Fight Planned Parenthood Cuts
A Massachusetts federal judge on Monday chided a Trump administration lawyer for continuing to argue that a coalition of states lacks standing to seek to block what it says is the effective defunding of Planned Parenthood, even as it only just received a lengthy list of new requirements for Medicaid reimbursement.
-
November 24, 2025
DOJ Demand For Pa. Transgender Patient Records Blocked
A Pennsylvania federal judge partially quashed part of a U.S. Department of Justice subpoena seeking health records for minors receiving gender-affirming care at The Children's Hospital of Philadelphia, ruling that the department lacked the statutory authority "for a rambling exploration" of medical files involving state-sanctioned medical care.
-
November 24, 2025
Full Fed. Circ. Rejects Bayer Petition In Xarelto Patent Case
The full Federal Circuit on Monday declined a petition from German pharmaceutical giant Bayer asking the appeals court to take a look at reviving patent claims related to its blood thinner medication Xarelto.
-
November 24, 2025
Hi-Tech Pharma CEO Beats Most Of Feds' Fraud Case
A Georgia federal jury acquitted Hi-Tech Pharmaceuticals' chief executive on the bulk of the conspiracy, fraud and money laundering charges leveled against him, rejecting allegations that he cheated his customers by drawing up bogus quality certificates.
-
November 24, 2025
Israeli Co. Can't Expand Contract Breach Suit Over $25M Deal
An Israeli smart packaging company can't enlarge a North Carolina Business Court contract breach suit, a judge ruled Monday, saying the amendment would "wholly transform" the case and prejudice defendant Sealed Air Corp.
-
November 24, 2025
Biotechs Go To Del. Chancery Over Cancer Drug Rights
A contract battle has broken out in the Delaware Chancery Court between two biotechs, each accusing the other of materially breaching a decade-old collaboration agreement governing rights to the cancer drug Jemperli.
-
November 24, 2025
FTC Abandons In-House GTCR Merger Case After Court Loss
The Federal Trade Commission formally dropped its administrative case challenging GTCR BC Holdings LLC's acquisition of a medical coatings supplier after an Illinois federal judge refused to put the deal on hold.
-
November 24, 2025
MVP: Cooley's Charity Williams
Charity Williams, a partner in Cooley LLP's life sciences corporate partnering and licensing practice, guided transformative pharmaceutical deals in 2025, including Capstan Therapeutics' $2.1 billion sale to AbbVie, Esobiotec's $1 billion sale to AstraZeneca and Advanced Instruments' $2.2 billion acquisition of Nova Biomedical, earning her a spot as one of the 2025 Law360 Life Sciences MVPs.
-
November 24, 2025
Ophthalmic Co. Hits Ch. 11 With $64M Debt, Eyeing Sale
Clearside Biomedical, a company developing treatments for eye diseases, has filed for Chapter 11 protection in Delaware bankruptcy court with $64 million in debt, saying it will attempt to sell its business during the case.
-
November 24, 2025
Justices Skip Appeal Challenging Denial Of Color TM
The U.S. Supreme Court on Monday declined an appeal from a medical supply company challenging a Federal Circuit ruling that rejected its bid to register a color trademark for dark green surgical gloves.
-
November 24, 2025
Justices Refuse Drug Price-Fixing Class Action
The U.S. Supreme Court said Monday that it will not review the Fourth Circuit's decision to back the dismissal of a proposed class action accusing drugmakers of conspiring and inflating the price of a medication for Huntington's disease.
-
November 21, 2025
Squires Issues 57 More PTAB Denials, Broken Out By Type
U.S. Patent and Trademark Office Director John Squires has rejected another 57 petitions challenging patents under the America Invents Act and for the first time differentiated between those denied for discretionary reasons and those denied on the merits.
-
November 21, 2025
DC Judge Axes Teva Challenge To Drug Price Program
A D.C. federal judge tossed a challenge by Teva Pharmaceuticals to the Medicare drug price negotiation program, marking the latest in a series of losses by drugmakers and trade groups seeking to upend the program.
-
November 21, 2025
Applied Therapeutics Investors Get 1st OK For $15M Deal
Biopharmaceutical company Applied Therapeutics Inc. and its investors have received initial approval of a deal that will end claims related to a 2024 new drug application, including a cash settlement of $15 million.
-
November 21, 2025
PBMs Say Gov't Benefits From Drug Rebates FTC Condemns
Caremark Rx, Express Scripts and OptumRx have been given permission to seek documents they say will show the government benefits from the same type of prescription drug rebating activity that's being targeted by the Federal Trade Commission's insulin pricing case.
-
November 21, 2025
'No Evidence' New Info Backs J&J Unit's Libel Suit, Court Told
A doctor being sued by Johnson & Johnson's bankrupt talc subsidiary pushed back on the unit's bid to revive its trade libel claim over a scientific article she wrote linking asbestos in talc to mesothelioma, arguing it failed to cite any evidence that undermines the court's finding that the article was a nonactionable statement of scientific opinion.
-
November 21, 2025
DLA Piper Adds Fenwick Emerging Growth, VC Expert In LA
DLA Piper is boosting its corporate team, bringing in a Fenwick & West LLP venture capital ace as a partner in its Los Angeles office.
-
November 21, 2025
Bausch Health Financial Stability Suit Permanently Dismissed
A New Jersey federal judge has dismissed for good a class action against Bausch Health Cos. Inc. and its top brass over claims that they misled shareholders about threats to the company's financial stability, finding that the second amended complaint includes inactionable challenged statements and fails to state a claim.
-
November 21, 2025
1st Circ. Clears IT Co. In Suit Over Zoll Patient Data Breach
An information technology company cannot be held liable for a data breach exposing the health information of patients of a unit of medical device maker Zoll Medical Corp, the First Circuit ruled, because the two companies did not have a business relationship permitting them to hold one responsible for another's conduct.
Expert Analysis
-
When Atty Ethics Violations Give Rise To Causes Of Action
Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.
-
What's New In FDA's Latest Cell And Gene Therapy Guidance
New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.
-
Trending At The PTAB: A Potential Barrier To Serial Challenges
New rules proposed by the U.S. Patent and Trademark Office may appear similar to previous rules at first glance, but are actually much broader in how they would limit petitioners' ability to challenge a patent more than once, say attorneys at Finnegan.
-
What's Changing For Cos. In New Calif. Hazardous Waste Plan
While the latest hazardous waste management plan from California's Department of Toxic Substances Control still awaits final approval, companies can begin aligning internal systems now with the plan's new requirements for environmental justice, waste and disposal reduction, waste criteria, and capacity planning, says Thierry Montoya at Frost Brown.
-
Fed. Circ. In September: The Printed Matter Doctrine Expands
The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens.
-
Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split
In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.
-
Series
Practicing Stoicism Makes Me A Better Lawyer
Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.
-
Broader Eligibility For AI-Related Patents May Be Coming
A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.
-
Series
The Biz Court Digest: Texas, One Year In
A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.
-
AI Product Safety Insights May Expand Foreseeability
Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.
-
Series
Law School's Missed Lessons: Educating Your Community
Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson.
-
Organ Transplant System Reforms Mark Regulatory Overhaul
Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.
-
Adapting To USPTO's Reduction Of Examiner Interview Time
Reported changes to the U.S. Patent and Trademark Office's examiner performance appraisal plan will likely make interviews scarcer throughout the application process, potentially influencing patent allowance rates and increasing the importance of approaching each interview with a clear agenda and well-defined goals, say attorneys at Polsinelli.
-
Federal Grantees May Soon Face More Limitations On Speech
If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.
-
5 Crisis Lawyering Skills For An Age Of Uncertainty
As attorneys increasingly face unprecedented and pervasive situations — from prosecutions of law enforcement officials to executive orders targeting law firms — they must develop several essential competencies of effective crisis lawyering, says Ray Brescia at Albany Law School.